美国FDA药品数据库-药物在线

商品名	申请号	产品号	申请类型	活性成分	剂型/给药途径	规格/剂量	RLD	RS	申请号原始批准/暂定批准日期	产品号批准日期	申请人	市场状态
QTERN	209091	001	NDA	DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE	TABLET;ORAL	10MG;EQ 5MG BASE	Yes	Yes	2017/02/27	2017/02/27	ASTRAZENECA AB	Prescription
QTERN	209091	002	NDA	DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE	TABLET;ORAL	5MG;EQ 5MG BASE	Yes	No	2017/02/27	2019/05/02	ASTRAZENECA AB	Prescription
QTERNMET XR	210874	001	NDA	DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE	TABLET, EXTENDED RELEASE;ORAL	2.5MG;1GM;EQ 2.5MG BASE	Yes	No	2019/05/02	2019/05/02	ASTRAZENECA AB	Discontinued
QTERNMET XR	210874	002	NDA	DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE	TABLET, EXTENDED RELEASE;ORAL	5MG;1GM;EQ 2.5MG BASE	Yes	No	2019/05/02	2019/05/02	ASTRAZENECA AB	Discontinued
QTERNMET XR	210874	003	NDA	DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE	TABLET, EXTENDED RELEASE;ORAL	5MG;1GM;EQ 5MG BASE	Yes	No	2019/05/02	2019/05/02	ASTRAZENECA AB	Discontinued
QTERNMET XR	210874	004	NDA	DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE	TABLET, EXTENDED RELEASE;ORAL	10MG;1GM;EQ 5MG BASE	Yes	No	2019/05/02	2019/05/02	ASTRAZENECA AB	Discontinued